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Steroid receptor coactivator‑3 (SRC‑3) regulates the activity of both nuclear hormone receptors and a 
number of key transcription factors. It is implicated in the regulation of cell proliferation, inflammation 
and in the progression of several common cancers including breast, colorectal and lung tumors. 
Phosphorylation is an important regulatory event controlling the activities of SRC‑3. Serine 857 is 
the most studied phospho‑acceptor site, and its modification has been reported to be important for 
SRC‑3‑dependent tumor progression. In this study, we show that the stress‑responsive  p38MApK‑MK2 
signaling pathway controls the phosphorylation of SRC‑3 at S857 in a wide range of human cancer 
cells. Activation of the  p38MApK‑MK2 pathway results in the nuclear translocation of SRC‑3, where it 
contributes to the transactivation of NF‑kB and thus regulation of IL‑6 transcription. The identification 
of the  p38MApK‑MK2 signaling axis as a key regulator of SRC‑3 phosphorylation and activity opens 
up new possibilities for the development and testing of novel therapeutic strategies to control both 
proliferative and metastatic tumor growth.
The steroid receptor coactivator 3 (SRC-3) is a transcriptional coactivator of the p160 family encoded by the 
gene nuclear receptor coactivator 3 (NCOA3). It was originally identified as a coactivator for nuclear  receptors1, 
but is now recognized as a coactivator of several other transcription factors including E2F transcription factor 
1 (E2F1)2, polyomavirus enhancer activator 3 (PEA3)3, activator protein-1 (AP-1)4,5, and nuclear factor-κB 
(NF-κB)6,7. Based on this broad spectrum of transcriptional activities, SRC-3 has been shown to play impor-
tant roles in a wide range of physiological processes, such as cell proliferation, cell survival, mammary gland 
 development8 and  metabolism9. Since 1997, when SRC-3 was found to be amplified in breast  cancer10 its role 
in cancer progression has been broadly investigated. It has been shown to be implicated in hormone-related 
cancers, such as  endometrial11,  ovarian12,  prostate13 and breast  cancer14, but also in in hormone-independent 
cancer types such as esophageal, squamous cell, colorectal, hepatocellular, pancreatic and non-small cell lung 
 cancer15. SRC-3 modulates various processes, for example cell  proliferation16 , development of  metastasis17, and 
resistances to anti-cancer  drugs18,19.
The function of the SRC-3 protein is highly regulated by post-transcriptional modifications through phos-
phorylation. SRC-3 is phosphorylated at multiple residues mediated by distinct protein kinases, suggesting that 
SRC-3 might be controlled by several different signaling pathways in health and  disease20,21. Among the different 
phosphorylation sites, the most frequently reported modification of SRC-3 is the phosphorylation at serine 857 
(S857)22. This phosphorylation has been shown to be important for regulation of estrogen receptor, androgen 
receptor and NF-κB-mediated  transcription20. In addition, more recent data indicate that phosphorylation at 
S857 is also essential for the ability of SRC-3 to promote lung and breast cancer progression and  metastasis23. 
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With regards to these observations, the protein kinase (or kinases) responsible for this specific phosphoryla-
tion of SRC-3 might be attractive therapeutic targets for treatment of lung and breast cancer. However, to date 
the identity of the protein kinases able to phosphorylate SRC-3 at S857 remains unclear. Suggested candidates 
include protein kinase A (PKA)20, I kappa B kinase (IKK)7 and the metabolic enzyme 6-phosphofructo-2-kinase/
fructose-2, 6-bisphosphatase 4 (PFKFB4)23.
Recently, SRC-3 was also reported to be a novel target for the extracellular regulated kinase 3 (ERK3)3,24. 
ERK3 is an atypical member of the Mitogen-Activated Protein Kinases (MAPKs) family of protein kinases. So 
far, little is known about the biological function of these atypical kinases. Our limited knowledge can partly be 
attributed to a lack of identified physiological substrates. The first physiological substrate identified for ERK3 was 
the MAPK-Activiated Protein Kinase (MAPKAPK)  MK525. However, besides being a regulator and downstream 
substrate of ERK3 and ERK4, the biological function of MK5 is unknown. Thus, the data indicating that SRC-3 
is a substrate for ERK3, could be an important step towards our understanding of the biological role of  ERK33,24.
In the present study, we aimed to confirm that S857 of SRC-3 is a bona fide substrate for ERK3 using the 
purified recombinant kinase. Unexpectedly, we found that ERK3 was not able to phosphorylate SRC-3 at S857 
efficiently in vitro. Instead, we observed that SRC-3 was efficiently phosphorylated at S857 by the MAPKAP 
kinases MK2 and MK5 in vitro. However, only MK2, a downstream effector of the activated  p38MAPK pathway, 
could mediate this specific phosphorylation in living cells. The phosphorylation of SRC-3 at S857 was efficiently 
inhibited by specific inhibitors of MK2 and MK3 in unstimulated cells and in cells with active  p38MAPK signal-
ing. Moreover, our data demonstrate that SRC-3 is an important regulator of the inducible expression of the 
pro-inflammatory cytokine IL-6 in response to activation of the  p38MAPK-MK2 signaling pathway by TNF-α.
Results
SRC‑3 is not a substrate of ERK3 in vitro. As SRC-3 was described as substrate for ERK3 in lung cancer 
 cells3, we aimed to confirm this finding in an in vitro approach. First, we tested whether recombinant active 
ERK3 could phosphorylate a recombinant GST fusion protein encoding the CBP-interacting domain (CID) of 
SRC-3 (SRC-3 aa 840–1,080). As shown in Fig. 1A, recombinant active ERK3 was unable to phosphorylate the 
GST-CID-SRC-3 WT (wild type) fusion protein. In contrast, when MK5, a bona fide ERK3 substrate, was added 
to the reaction efficient phosphorylation of GST-CID-SRC-3-WT was readily observed and was also seen after 
incubation with activated MK5 alone (Fig. 1A). Importantly, no phosphorylation was observed when a mutant 
version of the protein (GST-CID-SRC-3 S857A), in which serine 857 was replaced with alanine was used as sub-
strate (Fig. 1A). These findings indicate that SRC-3 is phosphorylated at S857 by the ERK3 downstream effector 
MK5 rather than by ERK3 itself.
Next, we aimed to determine if MK5 is also responsible for the phosphorylation of SRC-3 at S857 in vivo. We 
first generated a S857 phospho-specific SRC-3 antibody. The specificity of the antibody generated (P-S857-SCR-3 
antibody) was then tested in an in vitro kinase assay by incubating GST-CID-SRC-3 WT and GST-CID-SRC-3 
S857A with and without active MK5. The anti-P-S857-SRC-3 antibody specifically recognized the phosphoryla-
tion of GST-CID-SRC-3 WT at S857, while no signal was detected when incubating the mutated GST-CID-SRC-3 
S857A protein (Fig. 1B). The sensitivity of the anti-P-S857-SRC-3 antibody was then determined by Western-
blot analysis of a serial dilution of MK5-phosphorylated GST-CID-SRC-3 WT fusion protein revealing that 
the signal detected with this antibody was linear over a wide range of concentrations of phosphorylated SRC-3 
(Fig. 1C). Next, we determined whether the anti-P-S857-SRC-3 antibody was able to discriminate between 
unphosphorylated SRC-3 and SRC-3 phosphorylated at S857 in vivo in mammalian cells. The human lung cancer 
cell line H1299 was transfected with expression vectors encoding either SRC-3 WT or SRC-3 S857A. Western-
blot analysis confirmed the specificity of the anti-P-S857-SRC-3 antibody for the phosphorylation of S857, as a 
clear signal was only detected for SRC-3 WT but not for SRC-3 S857A (Fig. 1D). In a final step, we confirmed 
that the anit-P-S857-SRC-3 antibody could also discriminate between endogenous SRC-3 phosphorylated or 
unphosphorylated at S857. After immunoprecipitation of endogenous SRC-3 from extracts of H1299 cells, the 
precipitated SRC-3 was split into two fractions and one fraction was treated with lambda phosphatase. Western-
blot analysis showed that the anti-P-S857-SRC-3 antibody detected a signal only in the untreated fraction, and 
not in the fraction treated with lambda phosphatase (Fig. 1E). Taken together these results clearly demonstrate 
both the sensitivity and the specificity of the newly generated anti-P-S857-SRC-3 antibody.
SRC‑3 is phosphorylated at S857 by the MAPKAP kinases MK2 and MK5 in vitro. In the next 
experiments, we used the anti-P-S857-SRC-3 antibody to identify the kinase(s) that mediate the phosphoryla-
tion of SRC-3 at S857. As we could not detect any efficient phosphorylation of SRC-3 by ERK3, but only by MK5 
(Fig. 1A,B), we examined the sequence surrounding serine 857 in SRC-3. This sequence (Y-N-R-A-V-S-L) is 
more closely related to the optimal phosphorylation site sequences for either a MAPKAPK or protein kinase A 
(X-R-X-X-S-L), than to recognition sequence for a proline-directed MAPK such as ERK3 (T/S-P) (Fig. 2A)26. To 
investigate and compare the preference of MAPKAPKs and MAPKs for the S857 phosphorylation site in SRC-3 
in vitro, we set up a kinase assay using the GST-CID-SRC-3 WT fusion protein as substrate. The amount of each 
kinase used in the assay (MAPKAPKs MK2 and MK5, and the MAPKs ERK2, ERK3 and p38α) was adjusted to 
give equal input of kinase activity of 0.1 units. Under these conditions, both active MK2 and MK5 phosphoryl-
ated SRC-3 at S857 efficiently, while active ERK2, ERK3 and p38α were unable to phosphorylate this residue 
(Fig. 2B). To further explore the dynamics of S857 phosphorylation by MK2 and MK5, in vitro kinase assays 
were performed in dose- (Fig. 2C) and time-dependent (Fig. 2D) manners. The results showed that phospho-
rylation of SRC-3 increased gradually both with increasing amounts of active MK2 and MK5 (Fig. 2C) and with 
increasing incubation time (Fig. 2D). Taken together, these experiments demonstrated that SRC-3-S857 is an 
in vitro substrate for both of MK2 and MK5.
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The  p38MApK signaling pathway controls the phosphorylation of SRC‑3 at S857 in vivo. MK2 
and MK5 are controlled by two different signaling pathways; while MK5 is located downstream of the atypical 
MAPKs ERK3 and ERK4, MK2 lies downstream of the  p38MAPK. First, we aimed to determine whether ERK3 
and MK5 are required in vivo for phosphorylation of SRC-3 at S857. Therefore, we analyzed the phosphoryla-
tion status of endogenous SRC-3 at S857 in H1299 lung cancer cells, which were transfected with siRNA against 
MK5 or ERK3. Loss of either MK5 or ERK3 did not affect the phosphorylation state of SRC-3 at S857 in these 
cell extracts (Fig. 2E). These results suggest that SRC-3 is not a physiological substrate of neither ERK3 nor MK5.
As the consensus sequence around S857 in SRC-3 resembles a MAPKAPK phosphorylation motif, it is pos-
sible that other MAPKAP kinases lying downstream of the MAPK’s ERK1/2 or  p38MAPK could be responsible for 
the phosphorylation of this site in vivo. To investigate this, we treated the lung cancer cell line H1299 with specific 
kinase inhibitors before analyzing the phosphorylation state of SRC-3 at S857. Since all of the MAPKAPKs except 
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Figure 1.  ERK3 does not phosphorylate SRC-3. (A) MK5, but not ERK3, phosphorylates SRC-3-S857 
in vitro. For in vitro kinase assay, either 300 ng of active recombinant ERK3 protein (83.5 kDa) or 50 ng active 
recombinant MK5 (54 kDa) or both was incubated with 2 μg GST or GST-CID-SRC-3 WT or GST-CID-
SRC-3 S857A in kinase buffer and 1 μCi [ϒ32P]-ATP. The reaction was carried out at 30 °C for 15 min. Proteins 
were resolved by SDS-PAGE gel and visualized by autoradiography. (B) In vitro kinase assay was performed 
by incubating 2 μg GST or wild type (WT) or mutant (S857A) GST-CID-SRC-3 fusion proteins with and 
without 50 ng active MK5 in the kinase buffer for 15 min. Serine 857 phosphorylation and total amount of 
GST-CID-SRC-3 WT and GST-CID-SRC-3 S857A fusion proteins were detected by Western-blotting using 
anti-P-S857-SRC-3 and anti-GST antibodies, respectively. The full-length blots are presented in supplementary 
figure S4. (C) MK5 phosphorylated GST-CID-SRC-3 fusion protein (2 μg) was diluted 2, 4, 8, 16 and 32 times 
before separation on SDS-PAGE followed by Western-blotting. The membrane was then probed with anti-
GST and anti-P-S857-SRC-3 antibodies. The full-length blots are presented in supplementary Figure S5. (D) 
H1299 wild type cells were seeded in 6-well plates and left overnight followed by transfection with 1 μg vector 
encoding either SRC-3 wild type-FLAG (SRC-3 WT-FLAG) or SRC-3 S857A-FLAG (SRC-3 S857A-FLAG). 
After 48 h of transfection, the cells were lysed. FLAG-tagged SRC-3 and level of serine 857 phosphorylation 
of SRC-3 in the lysate was detected by Western-blotting with anti-FLAG and anti-P-S857-SRC-3 antibodies, 
respectively. The full-length blots are presented in supplementary figure S6. (E) Endogenous SRC-3 protein 
was immunoprecipitated from H1299 cells. After the last wash step, half of the precipitate was treated for 
30 min with 400U lambda phosphatase. Western-blot was performed with anti-SRC-3 and anti-P-S857-SRC-3 
antibodies. The full-length blots are presented in supplementary Figure S7.
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Figure 2.  MK2 and MK5 phosphorylate SRC-3-S857 in vitro. (A) Schematic diagram of SRC-3 amino acid 
sequence (aa). Common phosphorylation sites are indicated above the sequence and the consensus sequence 
of the S857 phosphorylation site is indicated below. Preferred consensus sequences for phosphorylation by 
MAPKKAPK (i), PKA (ii) and MAPK (iii) are shown in the lower part of the figure; Hyd indicates hydrophobic 
aa, X indicates any amino  acid57. (B) MK2 and MK5 phosphorylates SRC-3 at S857 in vitro. The in vitro kinase 
assay was performed by incubating GST-CID-SRC-3 WT (2 μg) with 0.1U of different active kinases at 30 °C 
for 15 min. Phosphorylation of SRC-3-S857 in GST-CID-SRC-3 WT and the total amount of GST-CID-SRC-3 
WT was detected using anti-P-S857-SRC-3 and anti-GST antibodies, respectively. The full-length blots are 
presented in supplementary figure S8. (C,D) MK2 and MK5 phosphorylate SRC-3-S857 in a dose and time 
dependent manner in vitro. (C) An in vitro kinase assay was performed by incubating increasing amounts (5, 
10, 20 and 40 ng) of active MK2 or active MK5 together with 2 μg GST-CID-SRC-3 WT at 30 °C for 15 min. (D) 
An in vitro kinase assay was performed by incubating 100 ng of active MK2 or MK5 together with 2 μg GST-
CID-SRC-3 WT at 30 °C for different periods of time (5, 10, 15, 20 min). For both (C) and (D), anti-P-S857-
SRC-3 antibody was used to detect SRC-3-S857 phosphorylation and an anti-GST antibody visualize the input 
of GST-CID-SRC-3 WT fusion protein for each reaction. The full-length blots are presented in supplementary 
figures S9,S10. (E) Neither MK5 nor ERK3 phosphorylate SRC-3-S857 in vivo. H1299 cells were transfected 
with either 20 nM scrambled siRNA, siRNA against MK5 or against ERK3. After 48 h, the cells were lysed and 
SRC-3 was immunoprecipitated with anti-SRC-3 antibody. The immunoprecipitate (IP) and whole cell extracts 
(WCE) were analyzed by Western-blotting. The full-length blots are presented in supplementary figure S11.
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cells with the MKK1/2 specific inhibitor PD-184352 or with the  p38MAPKα/β specific inhibitor SB-202190. As 
shown in Fig. 3A, inhibition of MKK1/2 activity using PD-184352 (thereby inhibiting RSKs, MSKs and MNKs 
activity via ERK1/2) did not affect the phosphorylation of SRC-3 at S857. However, inhibition of the  p38MAPK 
activity using SB-202190, and thereby inhibition of MK2/3 (and MSK1/2 and MNK1/2), profoundly inhibited 
the phosphorylation of SRC-3.
Based on these findings, we aimed to further validate the role of the  p38MAPK signaling pathway in the regu-
lation of SRC-3 phosphorylation at S857. Therefore, we stimulated various cell lines with well-known  p38MAPK 
activators (TNF-α, anisomycin and sodium arsenite (SA)). All cell lines analyzed, namely the lung cancer cell 
lines H1299 (Fig. 3B) and A549 (Fig. 3C), the human embryonic kidney cell line HEK293 (Fig. 3D), the human 
cervical carcinoma cell line HeLa (Fig. 3E) and the human breast cancer cell line MDA MB 231 (Fig. 3F) showed 
an enhanced phosphorylation of SRC-3 at S857 upon exposure to the three  p38MAPK activators. In addition to 
this, when  p38MAPK activity was inhibited using SB-202190, the TNF-α and anisomycin-induced (Fig. 3G) and 
SA-induced (Fig. 3H) SRC-3 phosphorylation at S857 was not observed. Since the results were obtained by activa-
tion of the  p38MAPK signaling pathway using different types of  p38MAPK activators in several different cell lines, it 
indicates that the phosphorylation of SRC-3 at S857 by activation of  p38MAPK signaling is a general phenomenon.
Phosphorylation of SRC‑3 at S857 is dependent on MK2. The results from in vitro kinase assays 
and cell culture experiments with specific inhibitors suggest MK2 as a bona fide downstream target of  p38MAPK, 
rather than the MAPKAPKs downstream of ERK1/2, is the kinase responsible for phosphorylation of SRC-3 
at S857. To investigate this hypothesis further, we utilized mouse embryonic fibroblast (MEF) cells and bone 
marrow derived cells (BMDC) isolated from double knockout (DKO) mice lacking both MK2 and MK3. As the 
expression of both of these downstream kinases is required for  p38MAPK  stability27 and thus to ensure that our 
results reflect the loss of MK2/MK3 and not the resulting depletion of  p38MAPK, we re-expressed either wild type 
MK2  (MK2WT) or a kinase dead mutant of MK2  (MK2K72A) into the DKO cell lines. The three different cell lines 
(MK2/MK3−/−; MK2/MK3−/− + MK2WT; MK2/MK3−/− + MK2K72A) were then treated with the  p38MAPK pathway 
activators (TNF-α, lipopolysaccharide (LPS) or sodium arsenite (SA)), and the phosphorylation status of SRC-3 
at S857 was analyzed. In the MK2/MK3−/− cells and the MK2/MK3−/− cells expressing the kinase-dead MK2 
 (MK2K72A), none of the  p38MAPK pathway stimulants resulted in induction of S857 phosphorylation. However, 
SA and LPS induced S857 phosphorylation in the MK2/MK3−/− cells rescued with  MK2WT (MEF cell, Fig. 4A; 
BMDC cells, Fig. 4B). Overall, these results indicate that MK2 activity is required for phosphorylation of SRC-3 
at S857 in murine cells.
Next, we studied the role of MK2 (and MK3) for phosphorylation of SRC-3 at S857 in different human cancer 
cell lines. For these experiments, we used the specific MK2 kinase inhibitor PF-3644022. A549 cells pretreated 
with different doses of PF-3644022 were stimulated with TNF-α (Fig. 4C) and anisomycin (Fig. 4D). Increasing 
doses of PF-3644022 markedly inhibited TNF-α and anisomycin-induced MK2 activity, as shown by the decrease 
in phosphorylation of HSP27, a known substrate of  MK228. Moreover, PF-3644022 effectively prevented the phos-
phorylation of SRC-3 at S857 (Fig. 4C,D). Then, we used A549 cells where we knocked down endogenous SRC-3 
expression with a specific siRNA, and at the same time co-transfected the cells with vectors encoding siRNA 
resistant FLAG-tagged SRC-3 WT or the phosphorylation site mutant SRC-3-S857A. Analysis of ectopically 
expressed SRC-3 revealed that activation of the  p38MAPK pathway with TNF-α or anisomycin resulted in increased 
phosphorylation of SRC-3 at S857, which was prevented by pre-incubation with the MK2-inhibitor PF-3644022 
(Fig. 4E) (Supplementary Fig. S1A). No phosphorylation of SRC-3 was observed in the cells transfected with 
SRC-3-S857A. The effect of PF-3644022 on anisomycin-stimulated S857 phosphorylation was also observed for 
endogenous SRC-3 protein in five human cell lines: HeLa (Fig. 4F), A549 (Fig. 4G), H1299 (Fig. 4H), HEK 293 
(Fig. 4I) and the breast cancer cell line MDA MB 231 (Fig. 4J). These results indicate that MK2 is responsible for 
phosphorylation of SRC-3 at S857 in response to activation of the  p38MAPK signaling pathway.
In the next step, we examined the dose and time dependent effect of TNF-α on MK2 activation (as indicated 
by phosphorylation of MK2 at T334), and the phosphorylation of SRC-3 at S857 in the breast cancer cell line 
MDA MB 231 and the lung cancer cell line A549. We observed that the phosphorylation of SRC-3 at S857 follows 
similar pattern as the activation of MK2, both in relations to dose in MDA-MB 231 cells (Fig. 5A), and time after 
stimulation in both MDA-MB 231 and A549 cells (Fig. 5B,C).
IKK is not involved in TNF‑α induced phosphorylation of SRC‑3 at S857. In unstimulated cells, 
the NF-κB proteins are sequestered in the cytoplasm by IκBs (Inhibitor of κB). When stimulated, IκB kinase 
(IKK) becomes activated and phosphorylates IκB proteins. This results in degradation of IκB and activation of 
NF-κB. IKK is composed of heterodimer of the catalytic IKK-α and IKK-β subunits and a regulatory subunit 
IKK-γ29. IKK-α and IKK-β are reported to phosphorylate SRC-3 at  S85720. In order to investigate whether IKK 
is involved in  p38MAPK-MK2 signaling pathway in phosphorylation of SRC-3, we studied the role of IKK-β and 
IKK-α on TNF-α-induced phosphorylation of SRC-3 at S857 in A549 cells using IKK-β inhibitor, BI-60590630 
(Fig. 6A) and siRNA against IKK-α (Fig. 6B) respectively. We found that neither exclusive inhibition of IKK-β 
activity (Fig. 6A) nor the exclusive inhibition of IKK-α expression (Fig. 6B) influenced the TNF-α-induced phos-
phorylation of SRC-3 at S857. However, at higher concentration of BI-605906 (Fig. 6A, last lane) and mutual 
inhibition of IKK-β activity and IKK-α expression together (Fig. 6B, last lane), a slight decrease in the phos-
phorylation of SRC-3 was observed. Moreover, no effect on the TNF-α-induced phosphorylation of HSP27 was 
observed when IKK-β activity (Fig. 6A) and IKK-α expression (Fig. 6B) were inhibited, thereby suggesting that 
IKK does not influence the  p38MAPK-MK2 pathway. Based on these findings, we conclude that MK2 is the major 
kinase phosphorylating SRC-3 at S857 in A549 cells.
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p38MApK and MK2 activity is important for the nuclear translocation of SRC‑3. SRC-3 contains 
both a nuclear localization signal (NLS) and a nuclear export signal (NES)31, and has been demonstrated to 
shuttle between the nucleus and cytoplasm depending on both its phosphorylation state, and interaction with 
the estrogen  receptor32. Having identified  p38MAPK and MK2 as crucial mediators of SRC-3 phosphorylation, 
we determined whether  p38MAPK and MK2 activity might also regulate subcellular distribution of SRC-3. As 
shown in Fig. 7A,B,E,F (left panels), immunostaining of SRC-3 in untreated A549 cells indicate abundant SRC-3 
protein both in the cytosol outside the nucleus, as well as in the nucleus. Upon stimulation with TNF-α, SRC-3 
translocates into the nucleus leading to almost complete nuclear localization of SRC-3. However, after pretreat-
ment with the specific  p38MAPK inhibitor SB-202190 (Fig.  7A,E (right panels)) and the specific MK2 kinase 
inhibitor PF-3644022 (Fig. 7B,F (right panels)), TNF-α stimulation did not lead to a significant translocation of 
SRC-3 into the nucleus.
Together with the observation that SB-202190 and PF-3644022 prevented phosphorylation of SRC-3 at S857, 
these findings strongly suggest that phosphorylation of SRC-3 at S857 by  p38MAPK and MK2 may be important 
for efficient nuclear localization of SRC-3.
Since phosphorylation of SRC-3 at S857 seems to be important for TNF-α-induced nuclear translocation 
of SRC-3, we further wanted to study whether the mutated SRC-3 S857A is translocated into nucleus when 
stimulated with TNF-α. For this, we generated A549 cells where we knocked out endogenous SRC-3 using 
CRISPR-Cas9 mediated gene editing (Fig. 7C) (Supplementary Fig. S3). When we transfected the SRC-3KO 
A549 cells with an expression vector encoding wild type SRC-3 and mutated SRC-3 S857A and stimulated with 
TNF-α, we found that SRC-3 WT was more efficiently translocated into nucleus than SRC-3 S857A (Fig. 7D,G). 
This finding further strengthens our hypothesis that phosphorylation of SRC-3 at S857 significantly enhances 
its nuclear translocation.
SRC‑3 is required for MK2‑mediated induction of IL‑6 mRNA expression in response to 
TNF‑α. After we established that the  p38MAPK-MK2 pathway is involved in phosphorylation of SRC-3 at 
S857, we aimed to explore the biological function of this modification. SRC-3 has been reported to co-activate 
NF-κB-mediated gene expression, and this was shown to depend on the phosphorylation of  S8577. Therefore, 
we aimed to determine the role of S857 in regulating NF-κB-mediated transcription in A549 cells. In order to 
investigate this, we transfected SRC-3KO A549 cells with a NF-κB-dependent luciferase reporter gene. A basal 
induction of luciferase activity in response to treatment with TNF-α was observed. Interestingly, we noticed a 
significant increase in TNF-α-induced luciferase activity when the SRC-3KO cells were co-transfected with an 
expression vector encoding wild type SRC-3 (Fig. 8A). Of note, this SRC-3 mediated increase in luciferase activ-
ity was not observed when the SRC-3KO cells were co-transfected with a vector encoding the mutated SRC-3 
S857A (Fig. 8A). This result shows that phosphorylation of SRC-3 at S857 is required for the ability of SRC-3 to 
co-activate NF-κB in response to TNF-α in A549 cells. Furthermore, knockdown of SRC-3 expression by spe-
cific siRNA or inhibition of MK2 activity with the inhibitor PF-3644022 both resulted in significant decrease in 
NF-κB-driven luciferase activity in response to treatment with TNF-α (Fig. 8B) (Supplementary Fig. S1B). These 
findings strongly indicate that both SRC-3 and MK2 activity are required for the induction of NF-κB-dependent 
transcription in response to TNF-α. Interleukin-6 (IL-6) is a well-known downstream target of NF-κB33. Earlier 
studies have shown that the phosphorylation of SRC-3 at S857 is necessary for the TNF-α stimulated IL-6 mRNA 
 expression20. When SRC-3WT and SRC-3KO A549 cells were stimulated with TNF-α, the TNF-α-induced IL-6 
mRNA expression was significantly lower in the SRC-3KO compared to the SRC-3WT A549 cells (Fig. 8C). This 
indicates a role of SRC-3 in IL-6 mRNA expression. MMP9 is another known downstream target of NF-κB34. 
When SRC-3WT and SRC-3KO A549 cells were stimulated with TNF-α, MMP9 mRNA expression increased 
substantially in both cell lines. There was however, no significant difference in the increase of MMP9 mRNA 
expression between SRC-3WT and SRC-3KO cell lines stimulated with TNF-α (Fig. 8D). These results indicate 
that although the expression of both IL-6 and MMP9 mRNA are induced by TNF-α only IL-6 expression is 
specifically dependent on SRC-3.
Figure 3.  Activation of  p38MAPK results in phosphorylation of SRC-3 at S857. (A)  p38MAPK but not ERK1/2 is 
involved in phosphorylation of SRC-3 at S857. H1299 cells were incubated with either 10 μM MEK1/2 inhibitor 
(PD-184352) or 10 μM  p38MAPK inhibitor (SB-202190) for 2 h before SRC-3 was immunoprecipitated (IP). The 
IP lysate and whole cell extract (WCE) were analyzed by Western-blotting using anti-P-S857-SRC-3, anti-SRC-3, 
anti-phospho ERK1/2 MAPK and anti-ERK2 antibodies. (B–F)  p38MAPK activation phosphorylates SRC-3 at 
S857. The full-length blots are presented in supplementary figure S12. H1299 (B), A549 (C), HEK 293 (D), HeLa 
(E) and MDA MB 231 (F) cells were stimulated with either 10 ng/ml TNF-α (15 min), 10 μg/ml anisomycin or 
250 μM sodium arsenite (SA) for 30 min. Unstimulated cells were used as control. The cells were lysed and the 
level of phosphorylation of SRC-3 at S857 and  p38MAPK at T180/Y182 was analyzed by Western-blotting using 
anti-P-S857-SRC-3, anti-SRC-3, anti-phospho-p38MAPK and anti-p38MAPK antibodies. The full-length blots 
are presented in supplementary figures S13–S17. (G,H) Inhibition of  p38MAPK activation prevents TNF-α and 
anisomycin-induced phosphorylation of SRC-3 at S857. A549 cells were seeded and left overnight. On the other 
day, the cells were pretreated either with DMSO or 10 μM SB-202190 for 30 min. Then they were stimulated 
with 10 ng/ml TNF-α (15 min) or 10 μg/ml anisomycin (G) or 500 μM sodium arsenite (SA) (H) for 30 min. 
Finally, the cells were lysed and level of phosphorylation of SRC-3 at S857, HSP27 at S82, total amount of SRC-
3, HSP27 and actin were detected by Western-blotting using appropriate antibodies. The full-length blots are 
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As MK2 was shown to be involved in NF-κB-dependent transcription (Fig. 8B), we performed experiments to 
investigate the role of MK2 in TNF-α stimulated IL-6 transcription in lung cancer cells. We transfected A549 cells 
with an IL-6 promoter-dependent luciferase vector. The cells were then stimulated with TNF-α after pretreatment 
with either the MK2 inhibitor PF-3644022, or DMSO as control. TNF-α-induced luciferase activity decreased 
significantly when MK2 activity was inhibited, suggesting involvement of MK2 activity in IL-6 transcription 
(Fig. 8E). Furthermore, we studied the role of MK2 in transcription of other NF-κB target genes namely, TNF 
receptor-associated factor 1 (TRAF1)35, IL-836 and Intercellular Adhesion Molecule 1 (ICAM1)37. A549 cells 
pretreated with DMSO or PF-3644022 for 30 min were stimulated with TNF-α for 5 h or left untreated. We found 
that mRNA expression of TRAF1 (Fig. 8F), IL-8 (Fig. 8G) and ICAM1 (Fig. 8H) increased significantly when 
stimulated with TNF-α compared to control. However, when MK2 activity was inhibited there was a significant 
decrease in mRNA expression of TRAF1 and IL-8 but not ICAM1. This indicates that MK2 is involved in regula-
tion of selective NF-κB target genes.
As  p38MAPK is an upstream activator of MK2 and SRC-3, we examined the role of  p38MAPK in NF-κB mediated 
transcription. First, we determined the role of  p38MAPK in NF-κB-dependent luciferase activity. The significant 
increase in TNF-α-induced NF-κB luciferase activity in A549-NF-κB-Luc cell decreased significantly when 
inhibited with SB-202190 (Fig. 8I). This suggests that  p38MAPK is involved in transcriptional activity of NF-κB. 
Next, we analyzed the involvement of  p38MAPK in TNF-α-stimulated IL-6 transcription in A549 cells. The TNF-
α-induced increase in IL-6 transcription activity was significantly decreased when  p38MAPK activity was inhibited 
(Fig. 8J). Furthermore, TNF-α-induced upregulation of mRNA expression of NF-κB target genes IL-6 (Fig. 8K), 
IL-8 (Fig. 8L) and MMP9 (Fig. 8M) were significantly inhibited when the  p38MAPK activity was inhibited in A549 
cells. This confirmed the role of  p38MAPK in regulation of NF-κB target genes that are upregulated by TNF-α.
Discussion
Although SRC-3 was first described as coactivator for nuclear receptors, it turned out that it can also act as 
coactivator for several other transcription factors, including  PEA33, AP-15,  TEAD438 and NF-κB6. A concept 
has emerged which indicates that SRC-3 can act as an integrator able to connect the activation of protein kinase 
signaling cascades to the control of specific transcriptional  programs39. This integration is controlled by specific 
kinases that phosphorylate SRC-3 at distinct sites. These phosphorylations may form a code that determine the 
ability of SRC-3 to be recruited to different transcription factors. The most frequent reported phosphorylation site 
of SRC-3 is  S85722. In the present study, we identified MK2 as the kinase responsible for both the basal, and the 
stress-induced phosphorylation of SRC-3 at S857 in a wide variety of cell types. This suggests that SRC-3 could 
be crucial for the control of various transcriptional programs via the  p38MAPK-MK2-SRC-3-S857 signaling axis.
Earlier studies suggested that SRC-3-S857 is a substrate of the atypical MAPK  ERK33,40. Unexpectedly, we 
observe in our study that recombinant ERK3 was not able to efficiently phosphorylate this site of SRC-3 in in vitro 
kinase assays. The main difference between our in vitro kinase assays and the previous studies was the source 
of the ERK3 protein. In the present study, we have used recombinant ERK3 purified from insect cells, while the 
previous studies used immunoprecipitated HA-tagged ERK3 protein transiently expressed in HEK 293 cells. For 
ERK3 from mammalian cells, it is well known that it forms strong and stable complexes with the protein kinase 
Figure 4.  MK2 phosphorylates SRC-3 at S857. (A,B) MK2 phosphorylates SRC-3 at S857 in mouse cell lines. 
Mouse embryonic fibroblast (MEF) cells (A) or bone marrow derived dendritic cells (BMDC) cells (B) derived 
from mice knocked out for MK2 and MK3 expression (MK2/MK3−/−), rescued with retroviral transduced 
GFP-MK2 wild type (MK2/MK3−/− + MK2WT), or rescued with retroviral transduced kinase dead MK2 (MK2/
MK3−/− + MK2K72A) were seeded and left overnight. Then the cells were treated with either 10 ng/ml TNF-
α, 250 μM SA or 5 ng/ml Lipopolysaccharide (LPS) as indicated for 30 min. Cell lysates were analyzed by 
Western-blotting using anit-P-S857-SRC-3, anti-SRC-3, anti-MK2 and anti-actin antibodies. *indicates the 
phosphorylated band. The full-length blots are presented in supplementary figures S20,S21. (C,D) PF-3644022 
prevents TNF-α and anisomycin-induced phosphorylation of SRC-3 at S857. A549 cells were seeded and 
left overnight. On the other day, the cells were pretreated with DMSO or 1, 2.5, 5, 10 μM of PF-3644022 for 
30 min followed by stimulation with either 10 ng/ml TNF-α (C) or 10 μg/ml anisomycin (D) for 30 min. 
Then the cells were lysed and level of phosphorylation of SRC-3 at S857, HSP27 at S82, total SRC-3 and total 
HSP27 were analyzed by Western-blotting using anti-PS857-SRC-3, anti-PS82-HSP27, anti-SRC-3 and anti-
HSP27 antibodies respectively. The full-length blots are presented in supplementary figures S22,S23. (E) MK2 
phosphorylates SRC-3 at S857 in the human lung adenocarcinoma cancer cell line A549. A549 cells were 
seeded in a 6-well plate and left overnight then co-transfected with 20 nM siRNA against SRC-3 and 1 μg vector 
expressing either siRNA resistant SRC-3 wild type-FLAG (SRC-3 WT-FLAG) or siRNA resistant SRC-3 S857A-
FLAG (SRC-3 S857A-FLAG). After 48 h, cells were treated with 10 ng/ml TNF-α (15 min) or 10 μM anisomycin 
for 30 min in absence or presence of 10 μM PF-3644022, which was added 30 min before the treatment. The 
cells were lysed and phosphorylation of SRC-3 at S857 was investigated by Western-blotting using anit-P-S857-
SRC-3, anti-FLAG and anti-actin antibodies. The full-length blots are presented in supplementary figure S24. 
(F–J) MK2 phosphorylates endogenous SRC-3 at S857 in human cell lines. HeLa (F), A594 (G), H1299 (H), 
HEK 293 (I) and MDA MB 231 (J) cells were seeded and left overnight. Then the cells were treated with 10 μM 
PF-3644022 for 30 min followed by stimulation with 10 μg/ml anisomycin for 30 min. Cells were lysed and 
level of phosphorylation of SRC-3-S857 and  p38MAPK were detected, before the total amount of SRC-3,  p38MAPK 
and actin were detected by Western-blotting using appropriate antibodies. Presented here is a representative 
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 MK525,41,42. Furthermore, this complex formation between ERK3 and MK5 is dependent on ERK3 phospho-
rylation at Serine 189. In this complex, MK5 becomes activated by ERK3, and this activation is dependent on 
the kinase activity of  ERK325,41,43. In our study, we observed that S857 of SRC-3 is a bona fide substrate of MK5 
in vitro, which may suggest that the kinase activity observed with HA-tagged ERK3 immunoprecipitated from 
HEK 293 could be due to co-precipitation of MK5. This hypothesis is further supported by the observation that 
MK5 is active in complex with ERK3, while MK5 is inactive in complex with kinase deficient  ERK33,40. Moreo-
ver, it was further supported by the observation that a functional S189 in ERK3 is required for phosphorylation 
of SRC-3 when ERK3 was immunoprecipitated from HEK 293 cells and used in an in vitro kinase assay. These 
findings strengthen the assumption that MK5 co-precipitating with ERK3 is the kinase responsible for SRC-3 
phosphorylation observed in these  studies40.
When examining the sequence surrounding S857 in SRC-3 (YNRAVSL) it became clear that this sequence 
more closely resembled the consensus for efficient phosphorylation by MK2 which is HydXRXXSX (where Hyd 
is a bulky hydrophobic residue), than a phosphorylation site for a proline-directed  MAPK44,45. In agreement 
with the MAPKAPK substrate consensus sequence, we found that S857 of SRC-3 was efficiently phosphorylated 
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Figure 5.  MK2-mediated phosphorylation of SRC-3 at S857 in response to TNF-α is dose and time dependent. 
(A) TNF-α stimulation phosphorylates SRC-3 and MK2 in a dose dependent manner. MDA MB 231 cells 
were seeded and left in incubator overnight. After that, the cells were treated with 0, 5, 10, 20 or 30 ng/ml of 
TNF-α as indicated in the figure for 15 min. Then the cells were lysed and the phosphorylation statuses of 
SRC-3 at S857 and MK2 at threonine (T) 334 as well as total protein amounts of these proteins and actin were 
examined by Western-blotting using anti-P-S857-SRC-3, anti-SRC-3, anti-phospho-MK2, anti-MK2 and anti-
actin antibodies. *indicates the phosphorylated band. The full-length blots are presented in supplementary 
figure S30. (B, C) TNF-α stimulation causes phosphorylation of SRC-3 at S857 and MK2 in a time dependent 
manner. MDA MB 231 (B) or A549 (C) wild type cells were seeded and left overnight. Then the cells were 
treated with 10 ng/ml TNF-α for 0, 15, 30, 60, 120, 240 or 360 min as indicated in the figures. The cells were 
lysed and phosphorylation status was examined by Western-blotting as described in (A) above. *indicates the 
phosphorylated band. The full-length blots are presented in supplementary figures S31,S32.
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by both MAPKAPK, MK2 and MK5, but not by MAP kinases in vitro. Using a phospho-specific antibody in 
combination with specific siRNAs and protein kinase inhibitors together with cells derived from mice deficient 
for MK2 and MK3 expression, we found that S857 is phosphorylated by MK2 in response to activation of the 
 p38MAPK signaling pathway in several human cancer cells, as well as in mouse embryonal fibroblast and bone 
marrow derived mouse cells. The MK2 inhibitor PF-3644022 used in this study is reported to inhibit MK2, MK3 
and MK5  activities46. Besides, the mouse cell lines used for validation of the MK2 involvement in SRC-3 phospho-
rylation at S857, were knocked out for both MK2 and MK3. Therefore, we cannot completely exclude that MK3, 
which has a much lower expression, is also involved in the SRC-3 phosphorylation at S857 in addition to MK2.
In order to investigate the downstream targets of  p38MAPK-MK2 induced phosphorylation of SRC-3 at S857, 
we studied the role of SRC-3 on the transcriptional activation of NF-κB. The phosphorylation of SRC-3 at S857 
was earlier described to be important for SRC-3 for complex formation with the transcription factor NF-κB, 
and the transcriptional activation of several cytokines including IL-6. This coactivation of NF-κB was linked to 
IKK-α-mediated phosphorylation of S857 in response to TNF-α  stimulation7. We investigated the role of IKK-β 
and IKK-α in TNF-α-induced phosphorylation of SRC-3 at S857 in A549 cells and found that neither IKK-β 
nor IKK-α was involved in the phosphorylation. Besides, in all the cancer cell lines examined in the present 
study, we observed that pretreatment with the MK2-specific kinase inhibitor PF-3644022 efficiently blocked the 
phosphorylation at S857 in response to TNF-α. This finding suggests that MK2 rather than IKK-α is the major 
TNF-α induced kinase responsible for phosphorylation of SRC-3 at S857 in cancer cells. However, it cannot be 
excluded that IKK-α might be responsible for regulation of this phosphorylation in other cell types or tissues.
The  p38MAPK-MK2 signaling axis plays a prominent role in controlling cytokine expression in response to 
proinflammatory cytokines and cellular stress. MK2 is well known for its post-transcriptional regulation of genes 
harboring adenine/uridine-rich elements (AREs) in their 3ʹ-untranslated region (3ʹ-UTR), including proinflam-
matory genes such as IL-6, TNF-α, and IL-1β47. Our data indicated that MK2 may also contribute to transcrip-
tional regulation of certain cytokines such as IL-6, TRAF1 and IL-8. However, due to the profound role of MK2 
in regulation of cytokine expression at the post-transcriptional level, it is difficult to exactly assess its role for 
the transcriptional regulation. Nonetheless, we could show that deletion of SRC-3 expression by CRISPR-Cas9 
mediated gene editing significantly decreased both, basic and TNF-α induced IL-6 mRNA expression in our A549 
lung cancer cell system. To further evaluate the role of MK2 in direct transcriptional activation, we employed 
reporter gene assays. Using a NF-κB-driven reporter assay, we could show that both SRC-3 and MK2 activity are 
required for full activation of the NF-κB promoter in response to TNF-α. Moreover, we also demonstrated that 
a functional S857 in SRC-3 is required for its ability to transactivate NF-κB in response to TNF-α.  p38MAPK was 
earlier described to be required for transcriptional activation of NF-κB and this activation was independent of 
IκB (Inhibitor of κB) phosphorylation or NF-κB translocation and DNA-binding48. Our data support this, and 
suggests that the requirement for a full NF-κB-mediated transcriptional activation might be the phosphoryla-
tion of SRC-3 at S857 via the activation of the  p38MAPK-SRC-3-MK2 axis. One specific role for MK2-mediated 
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Figure 6.  IKK-β and IKK-α are not involved in TNF-α induced phosphorylation of SRC-3 at S857. (A) IKK-β 
does not phosphorylate SRC-3 at S857. A549 cells pretreated with either DMSO or 1, 5, 10, 20 μM BI-605906 
for 30 min were stimulated with 10 ng/ml TNF-α for 15 min. Then the cells were lysed and Western-blotting 
was carried out to examine the phosphorylation of SRC-3 at S857, HSP27 at S82 and expression of total SRC-
3, HSP27, IκBα using anti-P-S857-SRC-3, anti-P-HSP27, anti-SRC-3, anti-HSP27 and anti-IκBα antibodies 
respectively. The full-length blots are presented in supplementary figure S33. (B) IKK-α does not phosphorylate 
SRC-3 at S857. A549 cells were transfected with either 10 nM scrambled siRNA, siRNA against IKK-α or left 
untransfected. After 48 h, the cells were either pretreated with 5 μM BI-605906 for 30 min or left untreated. 
Then the cells were either stimulated with 10 ng/ml TNF-α or left unstimulated for 15 min. Finally, the cells were 
lysed and Western-blotting was performed to examine the phosphorylation of SRC-3 at S857, HSP27 at S82 and 
expression of total SRC-3, HSP27, IKK-α and IκBα using anti-P-S857-SRC-3, anti-P-HSP27, anti-SRC-3, anti-
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complete nuclear translocation of SRC-3 is efficiently blocked by pretreatment of cells with the MK2 inhibitor. 
The requirement for SRC-3 in co-activation of genes downstream of TNF-α could be both cell and gene specific. 
In our experiments, we found that SRC-3 is required for TNF-α-induced IL-6 expression while it is dispensable 
for TNF-α-induced MMP9 expression.
The gene encoding for SRC-3 is amplified in 5–10% of breast cancer patients, and is often found to be overex-
pressed on both mRNA and protein  level49,50. Together with other members of the steroid receptor coactivators, 
such as SRC-1 and SRC-2, SRC-3 has been shown to be important for initiation and progression of estrogen 
receptor (ER) positive breast  cancer39. Recently, Dasgupta et. al. showed that SRC-3 is important for the abil-
ity to promote tumorgenicity in both ER-dependent (MCF7 cells) and -triple negative (MDA MB 231 cells) 
breast cancer  models23. Knock down of SRC-3 in these models inhibited either growth (MCF-7 cells) or both 
growth and metastasis (MDA MB 231 cells). As these phenotypes could not be rescued by expression of the 
phosphorylation-defective S857A mutant of SRC-3, these results suggest that the phosphorylation of SRC-3 at 
S857 might be crucial for breast cancer progression.
Since the present study demonstrates that MK2 is responsible for phosphorylation of SRC-3 at S857 in a 
wide variety of cell lines, including triple negative breast cancer cells (MDA MB 231 cells), the results indicate 
that the  p38MAPK-MK2-SRC-3 signaling axis could be a relevant therapeutic target in treatment of breast cancer.
Methods
Reagents. Penicillin/streptomycin (#P0781), DMSO (#472301), anisomycin (# A5862), LPS, Sodium arsen-
ite, PF-3644022 (#PZ0188) were purchased from Sigma-Aldrich, MO, USA. SB-202190 (#BML-EI294-001), 
PD-184352 (#ALX-270-471) were purchased from Alexis Biochemicals, CA, USA. Recombinant human TNF-α 
(#300-01A) was purchased from PeproTech, NJ, USA. Lambda phosphatase was purchased from New England 
Biolabs, MA, USA, BI-605906 was purchased from R&D systems, UK.
Generation of vectors. The mammalian expression vectors for expression of SRC-3 wild type (WT)-FLAG 
and SRC-3 S857A-FLAG as well as the vectors for expression of GST-CID-SRC-3 WT and GST-CID-SRC-3 
S857A were kind gifts from Dr. Weiwen Long, Baylor College of Medicine, Texas, USA and are described  in3. 
The expression vectors expressing siRNA resistant SRC-3 wild type (WT)-FLAG and SRC-3 S857A-FLAG were 
generated with quick-change mutagenesis (ThermoFisher Scientific, MA, USA) using the primers SRC-3siRF 
and SRC-3siRR (listed in Table 2) to introduce four silent mutations in the binding sequence for siRNA. The 
luciferase reporter vector κB-ConA-luc containing the binding site for NF-κB was kindly provided by Dr. Estelle 
Sontag, University of Texas South Western Medical Center, Texas, USA and is described  in51. The plasmids 
PX458 (Addgene # 48138) and eSpCas9 (1.1) (Addgene # 71814) were a kind gift from Dr. Feng Zhang (MIT). To 
generate vector PX458 (1.1) for delivery of a Cas9 enzyme with less of target activity as described by Slaymaker 
et. al. the 2,281 base pair (bp) ApaI-BsmI fragment of the plasmid  PX45852 was exchanged with corresponding 
fragment derived from the plasmid eSpCas9 (1.1)53. The reporter gene vector pGL3-IL-6-promoter was gener-
ated by cloning of a 1,136 bp KpnI-Hind III fragment, containing the IL-6 promoter (1,186 bp) amplified from 
human genomic DNA by PCR using the primers IL-6-prom F and IL-6-prom R (listed in Table 2), into the vector 
pGL3-basic (Promega, WI, USA) linearized with the restriction sites KpnI and Hind III.
Figure 7.  Activation of  p38MAPK and MK2 is required for efficient nuclear translocation of SRC-3 in response 
to TNF-α. (A,B)  p38MAPK and MK2 is involved in nuclear translocation of SRC-3. A549 WT cells were seeded 
on coverslip and left overnight. The next day, cells were treated with either DMSO, 10 ng/ml TNF-α or 
SB-202190 (A) or 10 μM PF-3644022 (B) separately, or in combination with SB-202190 (A) or PF-3644022 
(B) for 30 min followed by TNF-α stimulation for 60 min. Representative images of the SRC-3WT A549 cells 
stained for SRC-3 (red) using anti-SRC-3 antibody and nucleus ( blue, DAPI). The specificity of the antibody 
for SRC-3 was verified using SRC-3 KO cells (Supplementary Fig. S2A,B). (C) Generation of SRC-3KO A549 
cells. Expression of SRC-3 and actin in SRC-3WT and SRC-3KO A549 cells were analyzed by Western-blotting. 
(D) SRC-3 WT is more efficiently translocated into nucleus than SRC-3 S857A in response to TNF-α. SRC-3KO 
A549 cells were seeded in 24 well plate and left overnight. The next day, the cells were transfected with 200 ng 
of vector expressing either SRC-3 wild type (WT)-FLAG or SRC-3 S857A-FLAG. After 48 h, the cells were 
either stimulated with 10 ng/ml TNF-α for 60 min or left unstimulated. Representative images of the SRC-3KO 
A549 cells stained for SRC-3 (red, anti-SRC-3) and nucleus (blue, DAPI). (E–G) Quantitative presentation of 
the distribution of SRC-3 in conditions described in (A,B,D) respectively. The cellular localization of SRC-3 
was determined as either cytoplasmic and nuclear or mainly nuclear. The SRC-3 overlapping nucleus (DAPI) 
is considered nuclear and the SRC-3 overlapping the nucleus and present around and outside the nucleus is 
considered cytoplasmic + nuclear. For quantification, minimum 100 cells were counted for each condition 
described in (A,B,D) and expressed in percentage. Data in (E,F,G) are presented as mean ± SD of three 
replicates. Unpaired t-test was used for analysis of significance between groups compared in the figure. *P < 0.05, 
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Cell lines, siRNA and transfection. MDA MB 231 (American Type Culture Collection (ATCC) Virginia, 
USA, HTB-26), H1299 (ATCC CRL-580), A549 (ATCC CCL-185), HeLa (ATCC CCL-2), HEK 293 (ATCC 
CRL-11268), Mouse Embryonic Fibroblast (MEF) and Balb/c mouse bone marrow derived dendritic cells 
(BMDC) cells were maintained in Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich (D 5796)) supplemented 
with 10% fetal bovine serum (FBS) (Millipore, MA, USA, TMS-013-B), penicillin (100 units/ml) and strepto-
mycin (100 mg/ml) in a humidified 5%  CO2 atmosphere at 37 °C. Cell lines were authenticated by comparing 
DNA profiles of the cell lines with the reference cell lines. Cell lines were routinely screened for mycoplasma 
and mycoplasma-free cells were used for all the experiments. Generation of MK2/3 KO and rescue MEF and 
BMDC cells are explained  in27. The A549-NF-κB-Luc cells (RC0002) were obtained from Panomics San Diego, 
CA, USA. These cells are stably transfected with a luciferase reporter gene, which is under the transcriptional 
control of NF-κB.
siRNA against target genes were transfected into A549 and H1299 with Lipofectamine 2,000 or 3,000 (Invit-
rogen, CA, USA) prepared in OptiMEM (ThermoFisher Scientific) according to the manufacturer’s instructions. 
Scrambled siRNA was used as control. The siRNA duplexes were purchased from ThermoFisher Scientific and 
are listed in Table 2. In each well of a 6-well plate, 3 ×  105 cells were seeded and left overnight in incubator, then 
the cells were transfected with 20 ng/ml target siRNA or scrambled siRNA. The cells were lysed and lysates were 
harvested after 48 h. Successful knockdown was verified by Western-blotting analysis using antibodies listed in 
Table 1. Vectors were transfected into HeLa cells with Lipofectamine 2,000 or 3,000 (ThermoFisher Scientific), 
into A549 and H1299 with Lipofectamine LTX plus (ThermoFisher Scientific) and into HEK 293 cells with Trans 
IT-LT1 reagent (Mirus, WI, USA) according to the manufacturer’s instructions.
SRC‑3 knock out by CRISPR‑Cas9. Oligos for guide RNAs targeting SRC-3 were determined using 
the chopchop.cbu.uib.no  database54. The guide oligos (SRC-3-B) were ordered at ThermoFisher Scientific and 
are listed in Table 2. Guide oligos were cloned into the CRISPR-Cas9 expression vector PX458 (1.1) (Addgene 
#48138) as described  in52. A549 cells were sorted using BD FACSAria III (BD Biosciences, NJ, USA) 48 h after 
transfection and only those cells expressing GFP were seeded individually into 96 well plates. Knock out of 
SRC-3 was confirmed by Western-blot using Rabbit-anti-SRC-3 (5E11, Table 1). To identify indels, genomic 
DNA was extracted by diluting 10 × 104 cells in 30 μl of 50 mM NaOH, transferred to a tube and incubated for 
10 min at 95 °C. The sample was then placed on ice and 3 μl 1 M Tris pH 8.0 was added before the sample was 
centrifuged for 10 min at 10,000 rpm. 3 μl of the isolated genomic DNA was used to amplify the area of interest 
in the SCR-3 gene by PCR (30 cycles (98 °C for 5 s, 63 °C for 10 s, 72 °C for 30 s)) using Platinum SuperFi PCR 
Master Mix (ThermoFisher Scientific, #12358050) and SRC-3-A forward and reverse primers listed in Table 2. 
The PCR product was cloned into p-Zero-blunt vector (ThermoFisher Scientific, #K270040) and at least 8 indi-
vidual clones were sequenced by Sanger sequencing (DNA sequencing lab, University Hospital North Norway, 
Tromsø, Norway) using M13 primer listed in Table 2.
Generation of anti‑P‑S857‑SRC‑3 antibody. The anti-P-S857-SRC-3 antibody was raised in sheep and 
affinity purified on the appropriate antigen residues 852–862 of human SRC-3 [YNRAVS*LDSPV] by the Divi-
sion of Signal Transduction Therapy, University of Dundee, Scotland, UK.
Cell staining. About 4 ×  104 A549 cells were seeded on fibronectin coated coverslip in 24-well plate. Cells 
pretreated with either 10 μM PF-3644022 (MK2 inhibitor), SB-202190  (p38MAPK inhibitor) or 0.2 μl DMSO for 
30 min were treated with 10 ng/ml TNF-α for 60 min. Then, the cells were fixed with 500 μl 4% paraformalde-
hyde for 20 min and permeabilized with 500 μl 100% methanol for 5 min. After that the cells were blocked in 5% 
BSA for 20 min at room temperature. The cells were incubated in anti-SRC-3 antibody (Cell signaling Technol-
ogy #2126) for 1 h at room temperature. Immunostaining was performed using Alexa Fluor-568 conjugated with 
anti-rabbit antibody (Invitrogen, #A-10042) while nuclei were visualized by staining with 1 μg/ml DAPI. Images 
were captured using LSM 780 inverted confocal microscope (Zeiss) at 63X magnification. Images were acquired 
with ZEN Black ver. 2.3 (Carl Zeiss Microscopy) software and analysed with the Fiji software. At least 100 cells 
were studied for each group.
Luciferase reporter gene assay. For luciferase reporter gene assay, 4 ×  104 SRC-3WT or SRC-3KO A549 
cells were seeded in each well of a 24-well plate and left overnight. On the other day, cells were transfected with 
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120 ng of κB-ConA-luc or pGL3-IL-6-pro vector along with other required expression vectors for 48 h. After 
necessary treatment, cells were lysed and luciferase activity was determined using Pierce Firefly Luciferase Glow 
Assay Kit (ThermoFisher Scientific, #16177) or Luc-Screen (ThermoFisher Scientific) according to the manu-
facturers` instructions. The luminescence was measured using a CLARIOstar microplate reader (BMG Labtech, 
Ortenberg, Germany).
Expression of GST‑CID‑SRC‑3 in E. coli. GST fusion proteins were expressed in E. coli (BL21) as 
described  in25.
In vitro protein kinase assay. Generation of recombinant ERK3 is described  in25 and ERK3 specific activ-
ity was determined as described  in55 using myelin basic protein (MBP) as a substrate. Recombinant active p38α, 
ERK2, MK5 and MK2 were purchased from MRC PPU reagent and services, Dundee, UK. For in vitro protein 
kinase assay, the active kinase was incubated with wild type GST-CID-SRC-3 fusion protein (GST-CID-SRC-3 
WT) or mutant GST-CID-SRC-3 fusion protein (GST-CID-SRC-3 S857A) and 60 μM ATP in 50 μl kinase buffer 
(50 mM Tris HCl pH 7.5, 0.1 mM EGTA, 1 mM sodium vanadate, 1 mM DTT, 10 mM Mg(CH3COO)2/MgCl2). 
The reaction was carried out at 30 °C for 5–30 min and terminated with LDS Sample Buffer (ThermoFisher 
Scientific #NP0008) and Sample Reducing Agent (ThermoFisher Scientific #B0009) and finally analyzed by 
Western-blotting. For in vitro kinase assay using radioactive ATP, 1 μCi [ϒ32P] ATP (Amersham, Little Chal-
font, UK) was added in the ATP mix. Phosphorylated proteins were resolved by SDS-PAGE and visualized by 
autoradiography using the phosphorimager Fuji BAS-5000 (Fujifilm Life Science, Tokyo, Japan).
Western‑blot. Total cellular extract was obtained by lysis of the cells in MKK lysis buffer (50 mM Tris/HCl 
(pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% (w/v) Triton X-100, 1 mM sodium orthovanadate, 50 mM sodium fluo-
ride, 5 mM sodium pyrophosphate and 0.27 M sucrose) containing protease inhibitors cocktail tablets (Roche, 
Mannheim, Germany, #04693132001). The cellular lysate was centrifuged at 13,000g for 10 min at 4 °C. Pro-
tein concentration was determined using Pierce Bradford Assay Kit (ThermoFisher Scientific #23246) and was 
denatured by heating for 10 min at 70 °C along with LDS Sample Buffer (ThermoFisher Scientific #NP0008) 
and Sample Reducing Agent (ThermoFisher Scientific #B0009). For Western-blot analysis, equal amounts of 
protein were separated by running it on 4–12% Bis–Tris Gels (Invitrogen # NW04122BOX) for 35 min, at 200 V, 
120 mA in MES SDS Running buffer (Invitrogen #NP0002-02). See Blue Plus2 Prestained Standard (Invitrogen 
#LC5925), Super Signal Molecular Weight protein ladder (ThermoFisher Scientific, #84785,) and MagicMark 
XP Western Protein Standard (Invitrogen, #LC5602) were used as molecular weight markers. Then the proteins 
were transferred at 30 V, 150 mA for 2 h to Odyssey nitrocellulose membranes (LI-COR Biosciences, NE, USA 
#926–31092) using blotting buffer (48 mM Trisbase, 384 mM glycine and 20% methanol). After that, the mem-
brane was blocked for 1 h using Odyssey blocking buffer (PBS) (LI-COR #927-40000) followed by incubation in 
respective primary antibodies overnight at dilution as mentioned in Table 1 and washed thrice with 1XTBST for 
15 min then incubated with IRDye secondary antibodies (LI-COR Biosciences) in 1XTBST for 1 h. The mem-
Figure 8.  SRC-3 is required for MK2-mediated induction of IL-6 expression in response to TNF-α. (A,B) 
SRC-3 is involved in NF-κB activation. (A) SRC-3KO A549 cells were co-transfected with 120 ng κB-ConA-luc 
vector and 50 ng of either pSG5 empty vector, SRC-3 wild type (WT)-FLAG or SRC-3 S857A-FLAG vector. 
After 48 h TNF-α was added (if not other indicated 10 ng/ml for 5 h) before determination of luciferase activity 
relative to pSG5. (B) A549-NF-κB-Luc cells were transfected with scrambled siRNA or SRC-3 siRNA and 48 h 
later stimulated with TNF-α or left unstimulated. Nontransfected cells were pretreated with PF-3644022 for 
30 min before TNF-α treatment. Luciferase activities are shown relative to unstimulated scrambled siRNA. 
(C,D) SRC-3 is involved in TNF-α-induced IL-6 expression. SRC-3WT and SRC-3KO A549 cells were stimulated 
with TNF-α for 2 h or left unstimulated. mRNA expression of IL-6 (C) and MMP9 (D) were determined 
relative to GAPDH and TFRC. Fold changes are presented relative to unstimulated SRC-3WT cells. (E,J) MK2 
and  p38MAPK activity are required for transcription of IL-6. A549 cells were transfected with 120 ng pGL3-IL-
6-promoter vector and after 48 h treated for 30 min with 0.2 μl DMSO, 10 μM PF-3644022 (E) or SB-202190 
(J) followed by stimulation with TNF-α. Luciferase activities are shown relative to DMSO. (F–H) MK2 is 
involved in TNF-α induced TRAF1 (F), IL-8 (G) and ICAM1 (H) mRNA expression. A549 cells pretreated 
with DMSO or 10 μM PF-3644022 for 30 min were stimulated with TNF-α for 2 h or left unstimulated. MRNA 
expression were determined relative to GAPDH and TFRC. Fold changes are presented relative to DMSO. 
(I)  p38MAPK is involved in NF-κB-dependent luciferase activity. A549-NF-κB-Luc cells were pretreated with 
DMSO or SB-202190 and then stimulated with TNF-α or left unstimulated. Luciferase activities are shown 
relative to DMSO. (K–M)  p38MAPK is involved in TNF-α-induced IL-6 (K) and IL-8 (L) but not MMP9 (M) 
mRNA expression. A549 cells pretreated with DMSO or 10 μM SB-202190 for 30 min were stimulated with 
TNF-α or left unstimulated. MRNA expression were determined relative to GAPDH and TFRC. Fold changes 
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brane was washed thrice with TBST for a total of 15 min. Finally, fluorescent images of the blots were acquired 
on Odyssey Sa detection system (LI-COR Biosciences).
Immunoprecipitation. For immunoprecipitation, 2 ×  106 H1299 cells were seeded in a 100 mm dish. The 
cells were lysed and centrifuged as described in Western-blot section. The lysate obtained was cleared with acti-
vated Pierce Agarose resin (ThermoFisher Scientific). 2 mg of clarified lysate was incubated with 2 μg Mouse-
anti-FLAG (Sigma-Aldrich F1804) or Rabbit-anti-NCoA-3 (M-397) (Santa Cruz Biotechnology sc-9119) anti-
body (Table 1) overnight at 4 °C. Then 30 μl Protein G agarose (Millipore #16-266) was added to it and incubated 
for 60 min at 4 °C. The mixture was then transferred to spin column (Sigma-Aldrich #SC1000) and centrifuged. 
The spin column was washed twice with 500 µl ice cold MKK lysis buffer then with 50 mM TRIS chloride pH 
7.5. The immunoprecipitated protein was eluted by heating at 70  °C for 10 min in 60 μl LDS Sample Buffer 
(ThermoFisher Scientific #NP0008) and Sample Reducing Agent (ThermoFisher Scientific #B0009). The dena-
tured protein was separated by SDS PAGE, transferred and incubated with anti-SRC-3 and anti-P-S857-SRC-3 
antibody as described earlier.
RNA extraction, reverse transcription, quantitative real‑time PCR. Total RNA was obtained by 
lysing the cells with RLT Plus Buffer (Qiagen, Venlo, Netherlands #74136) supplemented with 1 M DTT (40 µl/
ml) followed by extraction with RNeasy Plus Mini kit (Qiagen #74136) according to the manufacturer’s instruc-
tions. Quantity and purity were determined using NanoDrop spectrophotometer (ThermoFisher Scientific). 
1 μg of total RNA was reverse transcripted to cDNA using the High capacity cDNA reverse transcription kit 
(ThermoFisher Scientific #4368813) supplemented with RiboLock RNase inhibitor (ThermoFisher Scientific 
#EO0381) (2 U/μl). Quantification of mRNA expression was determined using Light cycler 96 (Roche). Primer 
pairs for qRT-PCR were purchased from Sigma-Aldrich and are listed in Table 2. 2 μl cDNA was amplified for 
40 cycles (95 °C for 15 s, 60 °C for 1 min) in a 20 µl Power UP SYBR green master mix (ThermoFisher Scientific 
#25741) containing 200 nM of each primer. The relative expression of the target gene was normalized to the aver-
age expression of the two reference genes TFRC and GAPDH using the  2−∆∆Ct  method56.
Table 1.  List of antibodies. BD transduction laboratories, NJ, USA; Santa Cruz Biotechnology, CA, USA; Cell 
Signaling Technology, Danvers, MA, USA; Abnova, Taipei City, Taiwan; Invitrogen, CA, USA, Sigma-Aldrich. 
If not indicated, the antibody was used for Western-blotting (WB).
Antibody Source Identifier Dilution
1 Mouse-anti-AIB1 BD transduction laboratories 611,105 1:1,000
2 Rabbit-anti-SRC-3 (5E11) Cell signalling Technology 2,126 1:1,000 (WB)1:200 (immunostaining)
3 Rabbit-anti-NCoA-3 (M-397) Santa Cruz Biotechnology sc-9119 –
4 Rabbit-anti-ERK 2 (C-14) Santa Cruz Biotechnology sc-154 1:1,000
5 Mouse-anti-phospho p44/42 MAPK (ERK1/2) (T202 Y204) Cell Signaling Technology 9,106 1:1,000
7 Rabbit-anti-MK2 Cell Signaling Technology 3,042 1:1,000
8 Rabbit-anti-phospho-p38 MAPK (T180/Y182) Cell Signaling Technology 9,211 1:1,000
9 Rabbit-anti-phospho-MK2 (T334) Cell Signaling Technology 3,041 1:1,000
10 Rabbit-anti-p38 MAPK Cell Signaling Technology 9,212 1:1,000
11 Mouse-anti-FLAG Sigma-Aldrich F1804 1:1,000
12 Rabbit-anti-actin Sigma-Aldrich A2066 1:1,000
13 Rabbit-anti-GST (Z-5) Santa Cruz Biotechnology sc-459 1:1,000
14 Mouse-anti-PRAK (A-7) (MK5) Santa Cruz Biotechnology sc-46667 1:1,000
15 Mouse-anti-MAPK6 (ERK3) Abnova H00005597-M02 1:1,000
17 Sheep-anti-P-SRC-3-S857 Custom made by Division of Signal Transduction Therapy, (DSTT), University of Dundee, Dundee, UK 1:1,000
18 Goat-anti-mouse AF 800 Invitrogen A32730 1:10,000
19 Goat-anti-mouse AF 700 Invitrogen A21036 1:10,000
20 Goat-anti-rabbit AF 800 Invitrogen A32735 1:10,000
21 Goat-anti-rabbit AF-700 Invitrogen A21038 1:10,000
22 Rabbit-anti-sheep DyLight 800 Invitrogen SA5-10060 1:10,000
23 Donkey-anti-sheep AF 680 Invitrogen A-21102 1:10,000
24 Donkey-anti-rabbit AF 568 Invitrogen A-10042 1:4,000
25 Mouse-anti-IKK-α (B-8) Santa Cruz Biotechnology sc-7606 1:1,000
26 Rabbit-anti-IκB-α (C-21) Santa Cruz Biotechnology sc-371 1:1,000
27 Mouse-anti-HSP27 Millipore MAB88051 1:1,000
28 Rabbit anti-phospho-HSP27 (S82) Cell Signaling Technology 2,401 1:1,000
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Statistics. Values are presented as mean ± SD of at least three replicates. Data were analyzed with unpaired 
t-test using GraphPad prism software version 8.2.1 (CA, USA). Differences between groups were considered to 
be significant with P-values < 0.05.
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